BGI Health collaborates with Eastern Biotech a Life Sciences on non-invasive fetal Trisomy test for improving reproductive health in the Middle East

摘要

BGI Health, one of BGI's affiliates, established a partnership with Eastern Biotech 8t Life Sciences, a biotechnology company based in Dubai, on the project of introducing non-invasive fetal trisomy (NIFTY) test to the United Arab Emirates (UAE) and other Gulf Cooperation Council (GCC) countries in the Middle East. Fetal chromosomal aneuploidy disease is one of the most common birth defects, the leading cause of death for infants during the first year of life, such as Trisomy 21 (Down Syndrome), Trisomy 13 (Patau Syndrome), and Trisomy 18 (Edwards Syndrome). It will place an intolerable economic burden and adverse affect on their family members. Unfortunately, there is no effective method to cure this disease, but the key is to prevent by prenatal testing.